TIVC · Tivic Health Systems, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $126.0K | $86.0K | $70.0K | - | $126.0K | $140.0K | $334.0K | - |
| Cost of Revenue | - | - | $291.0K | $32.0K | $20.0K | - | $82.0K | $110.0K | $167.0K | - |
| Gross Profit | - | - | ($145.0K) | $54.0K | $50.0K | - | $44.0K | $30.0K | $167.0K | - |
| R&D | $1.85M | - | $858.0K | $655.0K | $335.0K | - | $422.0K | $302.0K | $256.0K | - |
| SG&A | $1.04M | - | $1.06M | $907.0K | $1.04M | - | $819.0K | $727.0K | $887.0K | - |
| Total Operating Expenses | $5.63M | - | $2.34M | $1.99M | $1.56M | - | $1.48M | $1.24M | $1.65M | - |
| D&A | $4.0K | - | $0 | $1.0K | $1.0K | - | $1.0K | $3.0K | $1.0K | - |
| Operating Income | ($5.63M) | - | ($2.48M) | ($1.93M) | ($1.51M) | - | ($1.43M) | ($1.21M) | ($1.48M) | - |
| Interest Expense | $0 | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.20M) | - | ($2.60M) | ($1.93M) | ($1.50M) | - | ($1.43M) | ($1.27M) | ($1.48M) | - |
| EPS - Basic | ($2.23) | - | ($1.97) | ($2.19) | ($2.52) | - | ($3.91) | ($5.44) | ($17.17) | - |
| EPS - Diluted | - | - | - | ($2.19) | ($2.52) | - | ($3.91) | ($5.44) | ($17.17) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.21M | $12.64M | $3.45M | $1.18M | $669.0K | $2.00M | $2.19M | $3.69M | $1.67M | $3.40M |
| Accounts Receivable | - | - | $19.0K | $13.0K | $13.0K | $69.0K | $9.0K | $16.0K | $74.0K | $174.0K |
| Inventory | $750.0K | $0 | $4.0K | $283.0K | $306.0K | $319.0K | $731.0K | $766.0K | $774.0K | $756.0K |
| Accounts Payable | $629.0K | $264.0K | $465.0K | $234.0K | $438.0K | $125.0K | $333.0K | $446.0K | $547.0K | $713.0K |
| Current Assets | $8.65M | $13.01M | $3.74M | $1.84M | $1.26M | $2.64M | $3.16M | $4.66M | $2.83M | $4.65M |
| Total Assets | $38.22M | $31.61M | $6.23M | $4.51M | $3.78M | $2.81M | $3.39M | $4.78M | $3.29M | $5.16M |
| Current Liabilities | $2.62M | $646.0K | $638.0K | $821.0K | $741.0K | $272.0K | $560.0K | $591.0K | $992.0K | $1.40M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $19.67M | $7.44M | $638.0K | $821.0K | $741.0K | $272.0K | $560.0K | $591.0K | $1.13M | $1.58M |
| Stockholders' Equity | $11.06M | $16.80M | $5.59M | $3.69M | $3.04M | $2.54M | $2.83M | $4.19M | $2.15M | $3.58M |
| Retained Earnings | ($59.03M) | ($52.60M) | ($49.62M) | ($46.98M) | ($45.04M) | ($43.54M) | ($42.06M) | ($40.63M) | ($39.37M) | ($37.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.01M) | - | - | - | ($889.0K) | - | - | - | ($1.67M) | - |
| Investing Cash Flow | ($7.0K) | - | - | - | ($526.0K) | - | - | - | - | - |
| Financing Cash Flow | ($44.0K) | - | - | - | $82.0K | - | - | - | ($61.0K) | - |
| CapEx | $0 | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($5.01M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | -115.1% | 62.8% | 71.4% | - | 34.9% | 21.4% | 50.0% | - |
| Operating margin | - | - | -1970.6% | -2248.8% | -2151.4% | - | -1135.7% | -861.4% | -443.4% | - |
| EBITDA margin | - | - | -1970.6% | -2247.7% | -2150.0% | - | -1134.9% | -859.3% | -443.1% | - |
| Net margin | - | - | -2060.3% | -2245.3% | -2145.7% | - | -1135.7% | -904.3% | -443.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.81 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 681.0% | 761.6% | 478.6% | - | 334.9% | 215.7% | 76.6% | - |
| SG&A / Revenue | - | - | 845.2% | 1054.7% | 1488.6% | - | 650.0% | 519.3% | 265.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.2% | - | -41.7% | -42.8% | -39.8% | - | -42.2% | -26.5% | -45.1% | - |
| Return on equity | -56.1% | - | -46.4% | -52.4% | -49.5% | - | -50.5% | -30.2% | -68.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.31 | 20.13 | 5.86 | 2.24 | 1.70 | 9.70 | 5.65 | 7.89 | 2.85 | 3.32 |
| Quick ratio | 3.02 | 20.13 | 5.86 | 1.90 | 1.29 | 8.53 | 4.34 | 6.59 | 2.07 | 2.78 |
| Cash ratio | 2.76 | 19.57 | 5.41 | 1.44 | 0.90 | 7.36 | 3.91 | 6.25 | 1.68 | 2.42 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.45 | 1.88 | 1.11 | 1.22 | 1.24 | 1.11 | 1.20 | 1.14 | 1.53 | 1.44 |
| Liabilities / Assets | 0.51 | 0.24 | 0.10 | 0.18 | 0.20 | 0.10 | 0.16 | 0.12 | 0.34 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.02 | 0.02 | 0.02 | - | 0.04 | 0.03 | 0.10 | - |
| Inventory turnover | - | - | 72.75 | 0.11 | 0.07 | - | 0.11 | 0.14 | 0.22 | - |
| Days sales outstanding | - | - | 55d | 55d | 68d | - | 26d | 42d | 81d | - |
| Days inventory outstanding | - | - | 5d | 3228d | 5585d | - | 3254d | 2542d | 1692d | - |
| Days payable outstanding | - | - | 583d | 2669d | 7993d | - | 1482d | 1480d | 1196d | - |
| Cash conversion cycle | - | - | -523d | 614d | -2341d | - | 1798d | 1104d | 577d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 1.0x | 0.5x | - | 9.3x | 6.3x | 14.5x | - |
| P / S | - | - | - | 42.5x | 21.8x | - | 208.8x | 189.9x | 93.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | 0.0% | -38.6% | -79.0% | - | -55.3% | -13.0% | -22.0% | - |
| Revenue CAGR (3y) | - | - | -23.1% | -45.4% | -39.9% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | 80.0% | -70.1% | - | -59.3% | -50.8% | 138.6% | - |
| Operating income growth (YoY) | -274.1% | - | -73.5% | -60.4% | -1.7% | - | 18.7% | 43.2% | 33.9% | - |
| Net income growth (YoY) | -312.9% | - | -81.4% | -52.5% | -1.4% | - | 18.7% | 40.4% | 30.0% | - |
| EPS growth (YoY) | - | - | - | 59.7% | 85.3% | - | -164.2% | -7671.4% | -15509.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 264.4% | 562.6% | 97.3% | -12.0% | 41.0% | -29.2% | -50.8% | 32.6% | -58.6% | -1.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$657.0K totalProduct Sales$656.0K · 99.8%
Shipping And Handling$1.0K · 0.2%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Tivic Health Systems against the 5 most active filers in the same SIC group.